Enzon Pharmaceuticals (ENZN)
Enzon Pharmaceuticals Cash and Equivalents: 46.21M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ENZN Cash and Equivalents Rankings
| Overall | 44th percentile | 2375 of 4272 |
| Sector | 57th percentile | 212 of 494 in Healthcare |
| Industry | 56th percentile | 67 of 155 in Biotechnology |
ENZN Cash and Equivalents Range, Past 5 Years
| Minimum | 21.36M | Sep 2007 |
| Maximum | 408.59M | Sep 2010 |
| Average | 165.27M |
About Cash and Equivalents
Cash and equivalents is cash or cash equivalents that a company possesses at any given time. Examples of cash equivalents are: money market accounts, treasury bills, and short term government bonds. Cash and cash equivalents are a business' most liquid assets. Cash on hand results from a positive cash flow statement.
Investors look at cash on hand as a reflection of a company's solvency and liquidity.
Learn More
You may also be interested in these ENZN related companies
ENZN News
$ENZN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3FPH
about 53 days ago by MarketBrief
about 53 days ago by MarketBrief
Icahn Capital's George Hebard Named as Director on Enzon Pharma (ENZN) Board
Feb 28, 5:17PM Street Insider
Feb 28, 5:17PM Street Insider
@TER_Intraday nice Fry Pan bottom in $ENZN since early Dec. Thanks for that.
about 123 days ago by 1nvestor
about 123 days ago by 1nvestor
EBR: Watchlist/worksheet/3Trading Ideas: $POT $IACI $ENZN http://stks.co/27m6
about 123 days ago by TER_Intraday
about 123 days ago by TER_Intraday
$ENZN http://stks.co/1VXa Biotech name. Flagging right under the 50MA. Watch the $7.15 level.
about 168 days ago by VexTrades
about 168 days ago by VexTrades
Enzon Presents Data From Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer
Dec 08, 6:15PM Marketwire
Dec 08, 6:15PM Marketwire
$ENZN http://stks.co/1Q88 Long setup for a short term trade. Tight price action in small wedge after recent strong buy volume
about 174 days ago by ToddinFL
about 174 days ago by ToddinFL
$ENZN http://stks.co/1ONJ Heavy short interest may have been taken out last week. Seth Klarman & Carl Icahn own 30% of shares.
about 175 days ago by drdebt
about 175 days ago by drdebt
Enzon Presents Clinical and Preclinical Data on mRNA Antagonists at 2011 AACR-NCI-EORTC Meeting
Nov 12, 1:00PM Marketwire
Nov 12, 1:00PM Marketwire
Enzon COO Ralph Del Campo steps down, CFO Ana I. Stancic promoted to COO
Oct 17, 4:25PM FlyOnTheWall
Oct 17, 4:25PM FlyOnTheWall
Enzon Pharma (ENZN) Promotes CFO Stancic to COO; Forms Special Committee
Oct 17, 4:14PM Street Insider
Oct 17, 4:14PM Street Insider
Enzon Announces Promotion of CFO Ana I. Stancic to COO; Continues to Serve as CFO
Oct 17, 4:14PM Benzinga
Oct 17, 4:14PM Benzinga
Iridian Asset Management Raises Stake in Enzon Pharmaceuticals, Inc. (ENZN) to 11.6%
Oct 06, 1:47PM Street Insider
Oct 06, 1:47PM Street Insider
Enzon $ENZN to Cut Workforce by 48% to Support R&D Activities, Sees Q3 Charge ~$3M
about 249 days ago by Street_Insider
about 249 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ENZN | 6.32 | +0.16 | +2.60% | 305.19M |
| DWSN | 24.95 | +0.07 | +0.28% | 197.60M |
| DWRI | None | None | None | |
| DWM | 39.25 | -0.11 | -0.27% | |
| DWCH | 12.06 | -0.17 | -1.39% | 75.25M |
| DWA | 17.85 | +0.13 | +0.73% | 1.500B |
| DW | 26.41 | -0.21 | -0.79% | 587.36M |
| DVY | 54.98 | -0.09 | -0.16% | |
| DVOX | 1.51 | +0.00 | +0.00% | 15.89M |
| DVN | 60.02 | -0.41 | -0.68% | 24.25B |
